Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015, Article ID 101904, 9 pages
http://dx.doi.org/10.1155/2015/101904
Research Article

Wenxin Keli versus Sotalol for Paroxysmal Atrial Fibrillation Caused by Hyperthyroidism: A Prospective, Open Label, and Randomized Study

1Department of Nuclear Medicine, Tianjin Medical University General Hospital, Anshan Road No. 154, Heping District, Tianjin 300052, China
2Department of Endocrinology, Tianjin Medical University General Hospital, Tianjin 300052, China

Received 27 June 2014; Revised 5 October 2014; Accepted 12 October 2014

Academic Editor: Myeong Soo Lee

Copyright © 2015 Zhaowei Meng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. S. Wann, A. B. Curtis, C. T. January et al., “2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” Journal of the American College of Cardiology, vol. 57, no. 2, pp. 223–242, 2011. View at Publisher · View at Google Scholar
  2. V. Fuster, L. E. Rydén, D. S. Cannom et al., “2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society,” Journal of the American College of Cardiology, vol. 57, no. 11, pp. e101–e198, 2011. View at Google Scholar · View at Scopus
  3. G. Y. Lip and H.-F. Tse, “Management of atrial fibrillation,” The Lancet, vol. 370, no. 9587, pp. 604–618, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. R. P. Steeds, A. S. Birchall, M. Smith, and K. S. Channer, “An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation,” Heart, vol. 82, no. 2, pp. 170–175, 1999. View at Google Scholar · View at Scopus
  5. T. Sanna and V. Di Lazzaro, “Thromboembolic risk management in paroxysmal atrial fibrillation after brain haemorrhage,” International Journal of Stroke, vol. 6, no. 1, pp. 92–93, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. M. E. Cain and A. B. Curtis, “Rhythm control in atrial fibrillation—one setback after another,” The New England Journal of Medicine, vol. 358, no. 25, pp. 2725–2727, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Roy, M. Talajic, S. Nattel et al., “Rhythm control versus rate control for atrial fibrillation and heart failure,” The New England Journal of Medicine, vol. 358, no. 25, pp. 2667–2677, 2008. View at Google Scholar
  8. C. T. Sawin, A. Geller, P. A. Wolf et al., “Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons,” The New England Journal of Medicine, vol. 331, no. 19, pp. 1249–1252, 1994. View at Publisher · View at Google Scholar · View at Scopus
  9. I. Klein and S. Danzi, “Thyroid disease and the heart,” Circulation, vol. 116, no. 15, pp. 1725–1735, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Bielecka-Dabrowa, D. P. Mikhailidis, J. Rysz, and M. Banach, “The mechanisms of atrial fibrillation in hyperthyroidism,” Thyroid Research, vol. 2, no. 1, article 4, 2009. View at Publisher · View at Google Scholar
  11. K. Wustmann, J. P. Kucera, A. Zanchi et al., “Activation of electrical triggers of atrial fibrillation in hyperthyroidism,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 6, pp. 2104–2108, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Komiya, S. Isomoto, K. Nakao, M. Hayano, and K. Yano, “Electrophysiological abnormalities of the atrial muscle in patients with paroxysmal atrial fibrillation associated with hyperthyroidism,” Clinical Endocrinology, vol. 56, no. 1, pp. 39–44, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Burashnikov, A. Petroski, D. Hu, H. Barajas-Martinez, and C. Antzelevitch, “Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation,” Heart Rhythm, vol. 9, no. 1, pp. 125–131, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Kalifa and U. M. R. Avula, “The Chinese herb extract Wenxin Keli: atrial selectivity from the Far East,” Heart Rhythm, vol. 9, no. 1, pp. 132–133, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Chen, S. Nie, H. Gao et al., “The effects of Wenxin Keli on P-wave dispersion and maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation: a meta-analysis of randomized controlled trials,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 245958, 9 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. X. Wang, Y. Gu, T. Wang, and C. Huang, “Wenxin Keli attenuates ischemia-induced ventricular arrhythmias in rats: involvement of L-type calcium and transient outward potassium currents,” Molecular Medicine Reports, vol. 7, no. 2, pp. 519–524, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. X. Xue, D. Guo, H. Sun et al., “Wenxin Keli suppresses ventricular triggered arrhythmias via selective inhibition of late sodium current,” Pacing and Clinical Electrophysiology, vol. 36, no. 6, pp. 732–740, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Minoura, B. K. Panama, V. V. Nesterenko et al., “Effect of Wenxin Keli and quinidine to suppress arrhythmogenesis in an experimental model of Brugada syndrome,” Heart Rhythm, vol. 10, no. 7, pp. 1054–1062, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. R. F. Wang, J. Tan, G. Z. Zhang, Z. W. Meng, and W. Zheng, “A comparative study of influential factors correlating with early and late hypothyroidism after 131I therapy for graves' disease,” Chinese Medical Journal, vol. 123, no. 12, pp. 1528–1532, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. W. Zheng, T. Jian, Z. Guizhi, M. Zhaowei, and W. Renfei, “Analysis of 131I therapy and correlation factors of Graves' disease patients: a 4-year retrospective study,” Nuclear Medicine Communications, vol. 33, no. 1, pp. 97–101, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Nakazawa, D. A. Lythall, J. Noh et al., “Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation,” European Heart Journal, vol. 21, no. 4, pp. 327–333, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. Z. H. Zhou, L. L. Ma, and L. X. Wang, “Risk factors for persistent atrial fibrillation following successful hyperthyroidism treatment with radioiodine therapy,” Internal Medicine, vol. 50, no. 24, pp. 2947–2951, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Kunii, T. Uruno, M. Matsumoto et al., “Pharmacological conversion of atrial fibrillation in the patients of Graves' disease,” Tokai Journal of Experimental and Clinical Medicine, vol. 37, no. 4, pp. 107–112, 2012. View at Google Scholar · View at Scopus
  24. E. Chan, M. Tan, J. Xin, S. Sudarsanam, and D. E. Johnson, “Interactions between traditional Chinese medicines and Western therapeutics,” Current Opinion in Drug Discovery & Development, vol. 13, no. 1, pp. 50–65, 2010. View at Google Scholar · View at Scopus
  25. X. J. Li and H. Y. Zhang, “Western healers in traditional Chinese medicine,” EMBO Reports, vol. 9, no. 2, pp. 112–113, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. J. D. Cheng, “Clinical observation of Wenxin Keli for the treatment of paroxysmal atrial ibrillation,” Chinese Journal of Information on Traditional Chinese Medicine, vol. 14, no. 8, pp. 55–56, 2007. View at Google Scholar
  27. Y. Dong, L. F. Xing, B. M. Li, and C. J. Tong, “Effect of Wenxin particle combine with fluvastatin on atrial remodelling in essential hypertension patients with atrial fibrillation,” Chinese Journal of Difficult and Complicated Cases, vol. 9, no. 8, pp. 566–568, 2010. View at Google Scholar
  28. S. R. Jin, “The effect of Wenxin Keli on P wave dispersion and the treatment for the paroxysmal atrial fibrillation,” Chinese Journal of Modern Drug Application, vol. 5, no. 12, pp. 92–93, 2011. View at Google Scholar
  29. N. Lv, D. Lin, and P. Lin, “Wenxin granule and low dose amiodarone in treating 60 cases of senile paroxysmal atrial fibrillation,” Fujian Journal of Traditional Chinese Medicine, vol. 41, no. 3, pp. 7–8, 2010. View at Google Scholar
  30. C. J. Zhang, “Effect of Wenxin granule treatment for paroxysmal atrial fibrillation patients,” Practical Pharmacy and Clinical Remedies, vol. 15, no. 11, pp. 737–739, 2012. View at Google Scholar
  31. M. L. Zhang, S. X. Jing, and H. Y. Zhang, “The effect of Buchangwenxin particle on dispersion of P wave in elder patients with diastolic cardiac dysfunction and paroxysmal atrial fibrillation,” Chinese Journal of Primary Medicine and Pharmacy, vol. 18, no. 20, pp. 2756–2758, 2011. View at Google Scholar
  32. Z. M. Zhang, P. Bai, and J. Z. Lin, “Wenxin Keli combined with ethylamine iodine skin ketone in treating senile hypertension paroxysmal atrial fibrillation,” Chinese Journal of Hypertension, vol. 16, no. 12, pp. 1134–1135, 2008. View at Google Scholar
  33. J. L. Lu, Y. Dong, and L. F. Xing, “The maintenance of sinus rhythm in patients with elderly hypertensive paroxysmal atrial fibrillation and the intervention of Wenxin Keli combined with fluvastatin,” Hebei Medical Journal, vol. 32, no. 24, pp. 3483–3484, 2010. View at Google Scholar
  34. Y.-J. Yan, Y.-M. Zhang, Y. Lu, S.-Y. Wang, and H.-D. Cui, “Effect of Wenxin-Keli combined with amiodarone on dispersion of P wave and C-reactive protein in patients with paroxysmal atrial fibrillation,” Chinese Journal of New Drugs, vol. 20, no. 15, pp. 1432–1434, 2011. View at Google Scholar · View at Scopus
  35. B. Gao, “Clinical observation of Wenxin Keli combined with valsartan on the maintenance of sinus rhythm in patients with hypertension with paroxysmal atrial fibrillation,” Chinese Community Doctors, vol. 14, no. 7, p. 54, 2012. View at Google Scholar
  36. F. C. Li, J. J. Tong, W. Hao, and Z. Ma, “The effect of Wenxin Keli combined with amiodarone for the treatment of paroxysmal atrial fibrillation in 32 cases,” Shanxi Journal of Traditional Chinese Medicine, vol. 29, no. 7, pp. 839–840, 2008. View at Google Scholar
  37. P.-Y. Xie and S.-H. Shen, “Effect of combination of Chinese and Western medicines on sinus rhythm maintenance in patients with auricular fibrillation after conversion,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 26, no. 7, pp. 644–646, 2006. View at Google Scholar · View at Scopus
  38. S. Z. Xu, “The study of prevention and curative effect of the Valsartan and Wenxin Keli on the paroxysmal atrial fibrillation,” Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine, vol. 8, no. 4, pp. 6–7, 2008. View at Google Scholar
  39. Q. H. Zheng and X. B. Zhang, “The effect of Wenxin Keli combined with amiodarone on the maintenance of sinus rhythm and serum MMP-9 in patients with paroxysmal atrial fibrillation,” Guiding Journal of Traditional Chinese Medicine and Pharmacology, vol. 19, no. 2, pp. 36–37, 2013. View at Google Scholar